10-K: Lineage Cell Therapeutics Reports Expanded Pipeline, Increased Losses

Lineage Cell Therapeutics, Inc. reported significant progress in its cell therapy pipeline and collaborations for 2025, alongside a substantial increase in net operating losses.

Summary

• Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell replacement therapies using its proprietary AlloSCOPE manufacturing platform.
• The company's lead program, OpRegen (RG6501), an allogeneic RPE cell replacement therapy for geographic atrophy (GA) secondary to dry-AMD, is in Phase 2a development under a worldwide collaboration with Roche and Genentech.
• OpRegen demonstrated durable improvement in best corrected visual acuity (BCVA) in Phase 1/2a patients, with a mean change of +6.2 letters at 36 months in Cohort 4.
• Lineage received a $5.0 million development milestone payment from Roche in December 2025 for OpRegen, with eligibility for up to an additional $615.0 million in milestone payments and tiered double-digit royalties.
• The second clinical-stage program, OPC1, an allogeneic oligodendrocyte progenitor cell therapy for spinal cord injuries (SCI), is in Phase 1 safety study using a novel delivery device.
• Preclinical programs include ReSonance (ANP1) for auditory neuropathy, in collaboration with William Demant Invest 2 Aps (WDI), which will fund up to $12 million in research costs over approximately three years.
• New research initiatives include ILT1 for large-scale production of islet cells for Type 1 Diabetes (T1D) and RND1, a novel hypoimmune iPSC line developed with Factor Biosciences for an undisclosed CNS indication.
• The company incurred operating losses of $36.6 million in 2025, up from $21.5 million in 2024, and a net loss attributable to Lineage of $63.5 million in 2025, compared to $18.6 million in 2024.
• Total revenues increased by 53% to $14.556 million in 2025, primarily driven by collaboration revenues of $13.609 million.
• Cash, cash equivalents, and marketable securities totaled $55.8 million as of December 31, 2025.
• The VAC platform and its related research and development efforts were abandoned in 2025, resulting in a non-cash pre-tax impairment charge of $14.8 million.
• The company's manufacturing operations are primarily conducted by its subsidiary, Cell Cure Neurosciences Ltd. (CCN), in Jerusalem, Israel, with over two-thirds of its workforce based there.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative report. While there is significant clinical and strategic progress with key pipeline assets and collaborations, the substantial increase in net losses and the ongoing need for significant capital, coupled with geopolitical risks to manufacturing, temper the positive developments.

Positives

• OpRegen (RG6501) demonstrated durable improvement in best corrected visual acuity (BCVA) in Phase 1/2a clinical study patients, with a mean change of +6.2 letters at 36 months in Cohort 4.
• Received a $5.0 million development milestone payment from Roche in December 2025 for OpRegen, with potential for up to an additional $615.0 million in future milestone payments and tiered double-digit royalties.
• Entered into a research collaboration agreement with William Demant Invest 2 Aps (WDI) for ReSonance (ANP1) for hearing loss, with WDI funding up to $12 million in preclinical development costs.
• Initiated the ILT1 research program to address large-scale production of undifferentiated pluripotent cells for potential Type 1 Diabetes treatment, with initial small-scale success.
• Successfully received a novel hypoimmune iPSC line (RND1) from Factor Biosciences, triggering a success payment and advancing the gene editing partnership.
• Demonstrated the ability to scale pluripotent cells with purity, potency, and regulatory quality required for clinical use through its AlloSCOPE platform, a valuable competitive differentiator.
• OpRegen has been granted Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA, potentially expediting its regulatory path.
• OPC1 has received RMAT designation and Orphan Drug designation from the FDA for acute spinal cord injuries.

Negatives

• Net loss attributable to Lineage increased significantly to $63.5 million in 2025 from $18.6 million in 2024.
• Loss from operations increased to $36.6 million in 2025 from $21.5 million in 2024.
• A non-cash pre-tax impairment charge of $14.8 million was recorded in 2025 due to the abandonment of the VAC platform.
• A significant negative change in the fair value of warrant liability of $35.7 million was recorded in 2025.
• The company will need to raise substantial additional capital to complete development and seek regulatory approval for its product candidates and to commercialize approved products.
• The withdrawal of the initial CIRM grant application for OPC1 in November 2025, although a revised application was submitted, highlights potential funding uncertainties.
• The company has incurred operating losses since inception and does not know if or when it will attain profitability, with an accumulated deficit of $467.0 million as of December 31, 2025.

Risks

• Dependence on the third-party collaboration with Roche for OpRegen's development and commercialization, with risks of termination, delays, or inconsistent economic interests.
• Potential failure or delay in transferring manufacturing process know-how to Roche or Roche's inability to manufacture comparable cells for OpRegen.
• Continued operating losses since inception and uncertainty of achieving profitability, requiring substantial capital for research and development.
• Challenges inherent in novel allogeneic cell therapies, including lengthy and expensive clinical development with high uncertainty of timing and outcome.
• Decisions regarding internal advancement versus strategic partnerships may not maximize shareholder value.
• Need to raise substantial additional capital, which may cause dilution to existing shareholders, restrict operations, or require relinquishing rights to product candidates.
• Risk of expending limited resources on particular product candidates and failing to capitalize on more profitable or successful alternatives.
• Loss of rights to key technologies if obligations under in-license agreements are not met.
• Significant operational risks due to all manufacturing being conducted in Jerusalem, Israel, including geopolitical conflict, cyberattacks, and economic instability, which could disrupt operations and workforce.
• Loss of key personnel or failure to attract and retain senior management and scientific staff could adversely affect the business.
• Changes in tax laws or regulations, including potential reallocation of taxable income among subsidiaries, could increase overall tax liability.
• Government-imposed bans or restrictions and religious, moral, and ethical concerns about human embryonic stem cells could prevent product development and marketing.
• Product candidates may be considered combination products by regulatory authorities, increasing complexity, cost, and timeline for approval.
• Surgical transplantation requirement for cell therapies exposes the company to additional regulatory, clinical, operational, and commercial risks.
• Disruptions at the FDA and other government agencies (e.g., lack of funding, shutdowns, policy changes) could delay development and approvals.
• Results of preclinical studies and early clinical trials are not necessarily predictive of future results, and interim data may change.
• Complex, highly regulated manufacturing of cell therapies, with limited clinical-scale and no commercial-scale experience, poses risks to quantity, quality, and cost.
• Lack of success or perceived lack of success of other cell therapy companies could negatively impact investor sentiment.
• Potential for side effects, adverse events, or safety risks associated with product candidates, leading to delays, discontinuation, or limited commercial profiles.
• Changes or disruptions to manufacturing operations could significantly delay and increase costs.
• Commercial success depends on market acceptance by physicians, patients, and third-party payors, which may be smaller than estimated.
• Significant competition from major pharmaceutical and biotechnology companies with greater resources.
• Potential product liability claims, which could incur substantial liability and costs.
• Lack of internal marketing and sales force or distribution capabilities, requiring reliance on third parties.
• Intellectual property may be insufficient to protect products, and risk of infringement claims from others.
• Reliance on third parties (CROs, suppliers) for development and manufacturing, with limited control over their performance.
• Volatility in the market price of common shares, influenced by various factors including clinical trial results, regulatory decisions, and macroeconomic conditions.
• Concentration of ownership by Broadwood Partners, L.P. could exert substantial influence over shareholder matters.
• Dilution of ownership interests from future equity financings or warrant exercises.
• Risk of non-compliance with NYSE American listing standards, potentially leading to delisting.
• Actions of activist shareholders could negatively affect business and stock value.
• Stringent and changing data privacy and security obligations, with potential for regulatory actions, litigation, and reputational harm.
• Vulnerability of information technology systems to cyberattacks, especially given operations in Israel.
• Negative impact from environmental, social, and corporate governance (ESG) matters or reporting.

Future Outlook

Lineage Cell Therapeutics expects to continue incurring significant operating losses for the foreseeable future as it advances its product candidates through development and seeks regulatory approval. The company anticipates needing substantial additional capital to fund operations, potentially through equity offerings, debt financings, grants, or strategic alliances. It plans to expand its manufacturing capabilities, possibly establishing new facilities, and expects to share updates on new research initiatives during 2026. The company believes its current cash, cash equivalents, and marketable securities will fund planned operations for at least twelve months from the filing date, supplemented by collaboration payments and ATM offering proceeds.

Management Comments

• Management believes cellular therapies aimed at entirely replacing dysfunctional or destroyed cells may have more durable, broader, or suitable applicability than traditional pharmaceutical products.
• Management views the term 'cell transplant' as more applicable than 'stem cell therapy' because they utilize stem cells solely as a source material to create and deliver mature, differentiated cells.
• Management believes the AlloSCOPE platform enables the capability to produce millions of doses of a consistent and cost-effective cell-based product.
• Management believes the AlloSCOPE platform can be applied across multiple programs, offering advantages in pursuing commercially successful, allogeneic, and off-the-shelf cell therapies.
• Management believes the company is uniquely positioned to capitalize on opportunities in non-oncology indications by applying its proprietary cell manufacturing technology.
• Management believes OpRegen could have a lasting benefit from a single administration or administered every several years, differing from current FDA-approved drugs requiring frequent injections.
• Management believes the input methodology represents the most appropriate measure of progress towards satisfaction of identified performance obligations in collaboration agreements.

Industry Context

StockSavvy.ai notes that Lineage Cell Therapeutics operates in the highly innovative and competitive cell therapy industry, which is characterized by rapid advancements and significant investment. The company's focus on allogeneic, differentiated cell transplants for non-oncology indications like dry-AMD and spinal cord injury positions it in an emerging branch of medicine. The recent FDA approvals of complement inhibitors for GA secondary to AMD (SYFOVRE and IZERVAY) highlight the increasing competition and evolving treatment landscape, though these differ from Lineage's cell replacement approach by not restoring vision. The conditional approvals of iPSC-derived therapies in Japan for Parkinson's and heart failure, while not directly comparable to Lineage's full marketing authorization pathway, underscore the global interest and nascent regulatory frameworks for pluripotent stem cell-derived products. The industry faces challenges in manufacturing scalability, cost-effectiveness, and regulatory precedent, which Lineage aims to address with its AlloSCOPE platform.

Comparison to Industry Standards

• Lineage's OpRegen Phase 1/2a results showing durable visual acuity improvement (+6.2 letters BCVA at 36 months in Cohort 4) are notable, as current FDA-approved complement inhibitors for GA (e.g., Apellis Pharmaceuticals, Inc.'s SYFOVRE and Astellas Pharma Inc.'s IZERVAY) have not clinically demonstrated improved or restored vision, only slowing decline.
• The company's AlloSCOPE platform, designed for allogeneic, scalable, consistent, and off-the-shelf pluripotent cell engineering, aims to address a significant industry challenge in cell therapy manufacturing, which is often complex and difficult to scale, a capability many competitors may not have achieved.
• Lineage's strategy of using mature, differentiated cells for transplantation, rather than undifferentiated stem cells, is a distinct approach compared to some other stem cell therapies, potentially mitigating certain regulatory and clinical risks associated with stem cell administration.
• The collaboration with Roche for OpRegen and WDI for ReSonance aligns with industry trends where smaller biotech companies partner with larger pharmaceutical entities to leverage resources for advanced clinical development and commercialization, similar to partnerships seen with companies like Regeneron Pharmaceuticals and Bayer AG in ophthalmology.

Corporate Governance

Legal Proceedings

• A motion for disclosure of documents was filed by HBL Hadasit Bio-Holdings Ltd. (HBL) against CCN in April 2023, alleging that an intercompany Collaboration and License Agreement between Lineage and CCN was not fairly priced and exploited CCN's resources. A third-party valuation firm's report in June 2025 stated the consideration paid by Lineage to CCN was insufficient. HBL notified the court on January 14, 2026, that settlement failed and moved to terminate current proceedings to potentially initiate separate ones. CCN responded on February 10, 2026, requesting denial of HBL's motion. The ultimate outcome is unpredictable and not currently estimable.

Related Party Transactions

• In February 2024, Lineage sold 6,730,770 common shares to Broadwood Partners, L.P., an affiliate of Neal Bradsher (a board member), and 96,155 common shares to Don Bailey (a former board member) in a registered direct offering.
• In January 2025, Lineage sold 7,894,737 common shares and an accompanying warrant to purchase up to 7,894,737 common shares to Broadwood Partners in the November 2024 registered direct offering.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and warrant exercises, as well as volatility in share price due to clinical trial outcomes, regulatory decisions, and macroeconomic factors.
• Employees, particularly those at the Jerusalem facility, face potential disruptions to operations and military call-up risks due to geopolitical conflicts in the Middle East.
• Customers (future patients) could benefit from the development of novel cell replacement therapies for serious medical conditions like dry-AMD, spinal cord injury, and hearing loss, but face risks of clinical trial failures or delays.
• Collaboration partners like Roche and WDI are integral to the development and commercialization of key product candidates, sharing risks and potential rewards.
• Creditors and investors are exposed to the company's significant operating losses and ongoing need for substantial additional capital, alongside the inherent risks of clinical-stage biotechnology.

Next Steps

• Continue to advance OpRegen (RG6501) in Phase 2a clinical development under the Roche collaboration.
• Continue the Phase 1 safety study of a novel delivery device for OPC1 and design a larger comparative clinical study.
• Advance preclinical development of ReSonance (ANP1) for hearing loss under the collaboration with WDI, aiming for readiness for human clinical trials.
• Continue the ILT1 research initiative to establish a scalable production modality for undifferentiated pluripotent cells for potential Type 1 Diabetes treatment.
• Evaluate the novel hypoimmune iPSC line (RND1) from Factor Biosciences for its ability to adapt to the AlloSCOPE platform and further performance criteria.
• Share updates on one or more new undisclosed research initiatives during 2026.
• Seek additional capital through equity offerings, debt financings, grants, or strategic alliances to fund future operations and development programs.
• Monitor and manage risks associated with operations in Israel, including geopolitical conflict and potential workforce disruptions.
• Address feedback from CIRM and pursue additional grant funding for OPC1 development.

Key Dates

Recommendation

Lineage Cell Therapeutics presents a mixed financial and operational picture. While the company has made significant clinical and strategic progress with its cell therapy pipeline, particularly OpRegen's durable visual acuity improvements and new collaborations, it also reported substantially increased net losses and faces ongoing capital requirements. The geopolitical risks associated with its manufacturing facility in Israel add a layer of uncertainty. For a seasoned investor, the promising pipeline and strategic partnerships offer long-term potential, but the significant financial burn rate and inherent risks of clinical-stage biotech warrant a 'hold' position, awaiting clearer paths to profitability and mitigation of operational risks.

Keywords

Cell Therapy, Biotechnology, Retinal Pigment Epithelial Cells, Geographic Atrophy, Dry Age-related Macular Degeneration, Spinal Cord Injury, Oligodendrocyte Progenitor Cells, Auditory Neuropathy, Pluripotent Stem Cells, Allogeneic, AlloSCOPE, Roche, Genentech, William Demant Invest, Factor Biosciences, SEC Filing, 10-K, Clinical Stage, Preclinical Development, Orphan Drug, RMAT, Manufacturing, Intellectual Property